Exploring the Role of Novel Bispecific Antibodies in R/R Diffuse Large B-Cell Lymphoma

The vast majority of non-Hodgkin‘s lymphoma (NHL) are B-cell NHLs, the most common being diffuse large B-cell lymphoma (DLBCL). While most patients with DLBCL respond to initial therapy, over a third will develop refractory or relapsed (R/R) disease. Although there is no established standard of care, recent approvals of bispecific T-cell engagers, emerging therapies, and developing data are changing the treatment paradigm in R/R DLBCL. In this activity, Drs. Allison Rosenthal and Yasmin Karimi will review the latest conference data on current and emerging bispecific antibodies for R/R DLBCL.

Click here to see full medical activity.